ABSTRACT
Uroacitide is a new anti-tumor drug, which is extracted from non-cytotoxic urine of the healthy human urine. In recent years, there have been many basic experiments and clinical trials focusing on its role in hematological diseases, especially in the treatment of myelodysplastic syndromes (MDS). There are also some basic researches on the treatment of other hematological diseases, which lays a foundation for further expanding its clinical indications and opens up a new way for the treatment of hematological diseases.
ABSTRACT
Uroacitide is a new anti-tumor drug, which is extracted from non-cytotoxic urine of the healthy human urine. In recent years, there have been many basic experiments and clinical trials focusing on its role in hematological diseases, especially in the treatment of myelodysplastic syndromes (MDS). There are also some basic researches on the treatment of other hematological diseases, which lays a foundation for further expanding its clinical indications and opens up a new way for the treatment of hematological diseases.
ABSTRACT
Objective To investigate the effect of CDA-Ⅱ on the cell cycle progression of breast cancer cells.Methods The effects of CDA-Ⅱ on growth curve, cell cycle progression and morphology of breast cancer cell lines MCF-7 and MDA-MB-231 were observed when CDA-Ⅱ and MCF-7 or CDA-Ⅱ and MDA-MB-231 were blended to cultivate in vitro, in comparison with the classical cell differentiation inducer ATRA. Results CDA-Ⅱ decreased the growth speed and inhibit proliferation ability in breast cancer cell lines MCF-7 and MDA-MB-231.It caused G0/G1 phase block of cell cycle and reduced the rate of S phase of breast cancer cells. Conclusion CDA-Ⅱ has remarkable effect of anti-cell-proliferation and can induce cell cycle block of G0/G1 on breast cancer cells. This results provide experimental bases for the treatment of breast cancer with CDA-Ⅱ.